BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Core Insights - BriaCell Therapeutics Corp. has added Mayo Clinic as a key clinical site for its ongoing pivotal Phase 3 clinical study in metastatic breast cancer [1][2] - The Phase 3 study now includes 69 active clinical sites across 15 states, enhancing the reach and potential patient enrollment for the trial [2] - The study evaluates BriaCell's lead candidate, Bria-IMT™, in combination with an immune checkpoint inhibitor against physician's choice in advanced metastatic breast cancer [3][4] Study Details - The primary endpoint of the study is overall survival (OS), with interim data analysis planned after 144 patient events (deaths) occur [4] - BriaCell has previously announced positive Phase 2 survival data for a similar patient population treated with the Bria-IMT combination regimen [4] - The Bria-IMT combination regimen has received FDA Fast Track designation, indicating its potential significance in cancer treatment [4] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [6]